Abstract:BackgroundMolecular subtype of breast cancer is associated with sentinel lymph node status. We sought to establish a mathematical prediction model that included breast cancer molecular subtype for risk of positive non-sentinel lymph nodes in breast cancer patients with sentinel lymph node metastasis and further validate the model in a separate validation cohort.MethodsWe reviewed the clinicopathologic data of breast cancer patients with sentinel lymph node metastasis who underwent axillary lymph node dissection between June 16, 2014 and November 16, 2017 at our hospital. Sentinel lymph node biopsy was performed and patients with pathologically proven sentinel lymph node metastasis underwent axillary lymph node dissection. Independent risks for non-sentinel lymph node metastasis were assessed in a training cohort by multivariate analysis and incorporated into a mathematical prediction model. The model was further validated in a separate validation cohort, and a nomogram was developed and evaluated for diagnostic performance in predicting the risk of non-sentinel lymph node metastasis. Moreover, we assessed the performance of five different models in predicting non-sentinel lymph node metastasis in training cohort.ResultsTotally, 495 cases were eligible for the study, including 291 patients in the training cohort and 204 in the validation cohort. Non-sentinel lymph node metastasis was observed in 33.3% (97/291) patients in the training cohort. The AUC of MSKCC, Tenon, MDA, Ljubljana, and Louisville models in training cohort were 0.7613, 0.7142, 0.7076, 0.7483, and 0.671, respectively. Multivariate regression analysis indicated that tumor size (OR = 1.439; 95% CI 1.025–2.021; P = 0.036), sentinel lymph node macro-metastasis versus micro-metastasis (OR = 5.063; 95% CI 1.111–23.074; P = 0.036), the number of positive sentinel lymph nodes (OR = 2.583, 95% CI 1.714–3.892; P < 0.001), and the number of negative sentinel lymph nodes (OR = 0.686, 95% CI 0.575–0.817; P < 0.001) were independent statistically significant predictors of non-sentinel lymph node metastasis. Furthermore, luminal B (OR = 3.311, 95% CI 1.593–6.884; P = 0.001) and HER2 overexpression (OR = 4.308, 95% CI 1.097–16.912; P = 0.036) were independent and statistically significant predictor of non-sentinel lymph node metastasis versus luminal A. A regression model based on the results of multivariate analysis was established to predict the risk of non-sentinel lymph node metastasis, which had an AUC of 0.8188. The model was validated in the validation cohort and showed excellent diagnostic performance.ConclusionsThe mathematical prediction model that incorporates five variables including breast cancer molecular subtype demonstrates excellent diagnostic performance in assessing the risk of non-sentinel lymph node metastasis in sentinel lymph node-positive patients. The prediction model could be of help surgeons in evaluating the risk of non-sentinel lymph node involvement for breast cancer patients; however, the model requires further validation in prospective studies.

Validation and Comparison of Models to Predict Non-Sentinel Lymph Node Metastasis in Breast Cancer Patients.

A Risk-Scoring Model for Predicting Lymph Node Metastasis in Early Gastric Cancer Patients: a Retrospective Study and External Validation

Role of Number of Sentinel Nodes in Predicting Non-Sentinel Node Metastasis in Breast Cancer

A New Model for Predicting Non-Sentinel Lymph Node Status in Chinese Sentinel Lymph Node Positive Breast Cancer Patients

Which nomogram is best for predicting non-sentinel lymph node metastasis in breast cancer patients? A meta-analysis

A new model to predict risk of nonsentinel lymph node status in Chinese sentinel lymph node-positive patients after neoadjuvant chemotherapy.

Development of a prediction model based on LASSO regression to evaluate the risk of non-sentinel lymph node metastasis in Chinese breast cancer patients with 1–2 positive sentinel lymph nodes

A Prospective Validation Cohort Study of a Prediction Model on Non-Sentinel Lymph Node Involvement in Early Breast Cancer.

Predicting Sentinel Lymph Node Metastasis in a Chinese Breast Cancer Population: Assessment of an Existing Nomogram and a New Predictive Nomogram.

Application of the Machine-Learning Model to Improve Prediction of Non-Sentinel Lymph Node Metastasis Status Among Breast Cancer Patients

Validation of the Memorial Sloan Kettering Cancer Center Nomogram for Predicting Non-Sentinel Lymph Node Metastasis in Sentinel Lymph Node-Positive Breast-Cancer Patients

[Risk Factors of Non-Sentinel Lymph Node Metastasis and Performance of MSKCC Nomogramin Breast Cancer Patients with Metastatic Sentinel Lymph Node].

A New Model for Predicting Nonsentinel Lymph Node Metastasis in Early-Stage Breast Cancer Using MMP15

Validation of MSKCC nomogram in predicting sentinel lymph node metastasis of breast cancer

[A Nomogram to Predict Non-Sentinel Lymph Node Metastasis for Breast Cancer Patients with Positive Axillary Sentinel Lymph Node].

A nomogram based on genotypic and clinicopathologic factors to predict the non-sentinel lymph node metastasis in Chinese women breast cancer patients

A mathematical prediction model incorporating molecular subtype for risk of non-sentinel lymph node metastasis in sentinel lymph node-positive breast cancer patients: a retrospective analysis and nomogram development

Development and validation of an ultrasonography and clinicopathological features-based nomogram for non-sentinel lymph node metastasis

Risk Factors and a Predictive Nomogram for Non-Sentinel Lymph Node Metastases in Chinese Breast Cancer Patients with One or Two Sentinel Lymph Node Macrometastases and Mastectomy.

Factors Predicting Non-Sentinel Lymph Node Status In Breast Cancer Patients With 1-2 Macrometastatic Positive Sentinel Lymph Nodes

Preoperative Nomogram for Predicting Sentinel Lymph Node Metastasis Risk in Breast Cancer: A Potential Application on Omitting Sentinel Lymph Node Biopsy